Wasatch Health Announces Expanded Investment Platform to Accelerate Life Sciences Growth in Utah and the Mountain West
January 28, 2026
Wasatch Health, formerly known as Med Venture Health, continues to expand its offerings with it’s revitalized name, reflecting the firm’s evolution and its growing role at the forefront of biotechnology and life sciences investment in Utah and the broader Mountain West.
Based in Salt Lake City, Wasatch Health is a premier private equity and growth investor focused on building and scaling innovative life sciences and medical technology companies. Founded by Travis Sessions, former CEO of Biomerics, the firm brings deep operational expertise and a long-standing track record of supporting companies across the medical device and biotech ecosystem.
The transition from Med Venture Health to Wasatch Health represents more than a rebrand—it signals a renewed commitment to supporting founders and management teams with flexible capital solutions, strategic guidance, and hands-on partnership throughout the company lifecycle. The Wasatch Health name reflects the firm’s regional roots, its connection to Utah’s rapidly expanding life sciences ecosystem, and its ambition to serve as a long-term partner to companies across the Mountain West.
Wasatch Health has historically invested in a wide range of medical device and life sciences companies and currently supports a strong portfolio that includes Biomerics, Canyon Labs, Stratus Medical, and Avia Vascular. These investments underscore the firm’s focus on differentiated technologies, capital-efficient growth, and strong clinical and commercial impact.
As part of this next phase of growth, Wasatch Health has expanded its leadership team with the addition of Brennen Brown, who joined the firm to help advance the firm’s investment platform and lead the development of a new growth equity strategy. This fund is designed to support later-stage life sciences companies that are ready to scale operations, accelerate commercialization, or pursue strategic expansion opportunities.
In addition to the growth equity strategy, Wasatch Health manages a structured capital fund, which provides flexible capital solutions at a wide range of amounts, and is actively working toward launching an SBIC fund. Together, these complementary investment vehicles provide the firm with a uniquely flexible platform, enabling Wasatch Health to invest across multiple stages and capital structures from early commercialization through mature growth.
As Wasatch Health continues to scale its platform, the firm is deepening relationships with aligned capital partners who share its long-term vision for advancing life sciences innovation in Utah and the Mountain West. Purposefully structured to support durable capital partnerships, Wasatch Health’s multi-fund approach aligns investors, operators, and founders around the shared goal of building and scaling impactful life sciences companies.
By combining operational experience, deep sector focus, and a diversified investment platform, Wasatch Health is positioned to play a pivotal role in advancing Utah’s life sciences ecosystem. The firm’s approach is designed to meet companies where they are and help propel them to their next stage of development whether that means scaling manufacturing, expanding clinical indications, entering new markets, or preparing for strategic transactions.
With its new name, expanded team, and growing suite of funds, Wasatch Health is reinforcing its mission to be a trusted partner for life sciences innovators and a catalyst for biotech and medtech growth throughout Utah and the Mountain West.